Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Clinical Trial
A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
This is a multicenter, single-arm, open-label, Phase 1 study to assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
|Status||Active, not recruiting|
|Start date||January 23, 2017|
|Completion date||September 2020|